Bernard Davitian

Bernard Davitian was the founder of DNA Therapeutics SASU, founded in 2009, where the title held was Director in 2009.
Current jobs include Director at Vanqua Bio, Inc. since 2021, Director at Endeavor BioMedicines, Inc., and Partner at Omega Fund Management LLC since 2020.
Former jobs include Chief Executive Officer at Neurotech Pharmaceuticals, Inc. (2005–2006), Vice President & Managing Director at Sanofi Ventures LLC (2012–2019), Director at Proteostasis Therapeutics, Inc., Director at KAHR Medical Ltd., Director at Lysosomal Therapeutics, Inc., Director at Upstream Bio, Inc. (2021–2023), Independent Director at Lexeo Therapeutics, Inc. (2020–2024), Chief Financial Officer & Executive Vice President at Transgene SA (1995–2000), Executive Vice President & Chief Financial Officer at Fovea Pharmaceuticals SA (2006–2010), Chief Financial Officer at Sanofi Pasteur SA (1994), Chief Financial Officer at Pasteur Merieux, Inc. (1994), Chief Financial Officer at Fortel Invest Oy (2000–2001), and Senior Auditor at Arthur Andersen LLP (1984–1986).
Education includes graduation from EM Lyon Business School in 1981 and an MBA from The Wharton School of the University of Pennsylvania in 1994.